Supplementary Materials Click here to download Supplementary Materials: Supplemental MaterialsSK.doc

Supplemental Materials

Supplemental Table 1. Beta Coefficients for the Interactions of Baseline and Change in Lipid Measures and time Relative to FMP on Carotid Intima-Media Thickness among Participants with Known Date of Final menstrual Period, N=131 women / 398 observations

	Progression	in cIMT,		Progression in cIMT,	
HDL-C Measures	mm/year		apoA Measures	mm/year	
	β (SE) ^a	P value		β (SE) ^b	P value
Model 1			Model 1		
Baseline HDL-C	-0.002(0.001)	0.04	Baseline apoA	-0.002(0.001)	0.02
Change in HDL-C	0.003(0.001)	0.008	Change in apoA	0.002(0.001)	0.08
Model 2			Model 2		
Baseline HDL-C	-0.002(0.001)	0.03	Baseline apoA	-0.002(0.001)	0.01
Change in HDL-C	0.003(0.001)	0.007	Change in apoA	0.001(0.001)	0.12
Model 3			Model 3		
Baseline HDL-C	-0.001(0.001)	0.11	Baseline apoA	-0.002(0.001)	0.02
Change in HDL-C	0.003(0.001)	0.004	Change in apoA	0.001(0.001)	0.11

^a Beta coefficients represent cIMT progression rate (mm/year) per SD unit of baseline HDL-C (SD=11.96 mg/dL) and change in HDL-C since baseline (6.15 mg/dL)

- ^b Beta coefficients represent cIMT progression rate (mm/year) per SD unit of baseline apoA (SD=23.69 mg/dL) and change in apoA since baseline (18.78 mg/dL)
 - Model 1: Adjusted for baseline age, time since FMP, race and education
 - Model 2: Adjusted for variables in model 1 plus time varying BMI and SBP
 - Model 3: Adjusted for variables in model 2 plus LDL-C, current use of CVD medications and log transformed hs-CRP

HDL-C Measures	Progression in cAl	D, mm/year	Presence of cPlaque	
	β (SE) ^a	P value	OR(95%CI) ^b	P value
Model 1				
Baseline HDL-C	-0.006(0.004)	0.14	0.99(0.92, 1.06)	0.77
Change in HDL-C	-0.005(0.004)	0.18	0.99(0.93, 1.05)	0.74
Model 2				
Baseline HDL-C	-0.005(0.004)	0.25	1.01(0.95, 1.08)	0.73
Change in HDL-C	-0.006(0.004)	0.11	0.99(0.933, 1.06)	0.80
Model 3				
Baseline HDL-C	-0.006(0.004)	0.20	1.02(0.95, 1.09)	0.62
Change in HDL-C	-0.006(0.004)	0.11	0.99(0.93, 1.06)	0.84

Supplemental Table 2. Beta Coefficients for the Interactions of Baseline HDL-C and Change in HDL-C and time Relative

to FMP on Carotid Adventitial diameter and Plaque Presence

^a Beta coefficients represent AD progression rate (mm/year) per SD unit of baseline HDL-C (SD=11.96 mg/dL) and change in HDL-C since baseline (6.15 mg/dL). For AD n=206 women/501 observations.
 ^b OR(95%CI) represents increases in odds of plaque presence per SD unit of baseline HDL-C (SD=11.96 mg/dL) and change in HDL-C since baseline (6.15 mg/dL) by time since FMP. For plaque n=213 women/531

observations.

Model 1: Adjusted for baseline age , time since FMP, race and education

Model 2: Adjusted for variables in model 1 plus time varying BMI and SBP

Model 3: Adjusted for variables in model 2 plus LDL-C, current use of CVD medications and logtransformed

hs-CRP

apoA Measures	Progression in c	AD, mm/year	Presence of cPlaque	
	β (SE) ^a	P value	OR(95%CI) ^b	P value
Model 1				
Baseline apoA	-0.003(0.005)	0.56	0.99(0.93, 1.05)	0.68
Change in apoA	0.002(0.004)	0.68	0.95(0.90, 0.99)	0.04
Model 2				
Baseline apoA	-0.003(0.005)	0.55	1.00(0.95, 1.07)	0.91
Change in apoA	0.002(0.004)	0.58	0.95(0.90, 1.00)	0.06
Model 3				
Baseline apoA	-0.003(0.005)	0.55	1.01(0.95, 1.07)	0.82
Change in apoA	0.002(0.004)	0.55	0.95(0.91, 1.00)	0.07

Supplemental Table 3. . Beta Coefficients for the Interactions of Baseline apoA and Change in apoA and time Relative to

FMP on Carotid Adventitial diameter and Plaque Presence

^a Beta coefficients represent AD progression rate (mm/year) per SD unit of baseline apoA (SD=23.69 mg/dL) and change in apoA since baseline (18.78 mg/dL). For AD n=206 women/501 observations.
^b OR(95%CI) represents increases in odds of plaque presence per SD unit of baseline apoA (SD=23.69 mg/dL) and change in apoA since baseline (18.78 mg/dL) by time since FMP. For plaque n=213

women/531 observations.

Model 1: Adjusted for baseline age, time since FMP, race and education

Model 2: Adjusted for variables in model 1 plus time varying BMI and SBP

Model 3: Adjusted for variables in model 2 plus LDL-C, current use of CVD medications and log transformed

hs-CRP